StockData
CVRx, Inc. logo

CVRx, Inc. (CVRX) stock

CVRXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$0.61−0.02 (-3.60%)

Close on Nov 13, 2026Market cap $16.18MP/E –Yield –

CVRx r&d expenses

Research and development expenses are spending on new products and technology.

CVRx's R&D Expenses for the twelve months ending Sep 30, 2026 was $11.87M, up 8.5% year over year. For fiscal 2025 it was $11.13M, up 0.0% from the year before. The highest annual figure on record is $11.63M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.13M+0.0%
FY2024Dec 31, 2024$11.13M-4.3%
FY2023Dec 31, 2023$11.63M+16.9%
FY2022Dec 31, 2022$9.95M+32.7%
FY2021Dec 31, 2021$7.50M+17.0%
FY2020Dec 31, 2020$6.41M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.66M-15.6%
Q2 FY2026Jun 30, 2026$3.13M+26.8%
Q1 FY2026Mar 31, 2026$3.08M+22.5%
Q4 FY2025Dec 31, 2025$3.00M+7.0%
Q3 FY2025Sep 30, 2025$3.15M+25.6%
Q2 FY2025Jun 30, 2025$2.47M-10.7%
Q1 FY2025Mar 31, 2025$2.52M-17.7%
Q4 FY2024Dec 31, 2024$2.81M+25.2%
Q3 FY2024Sep 30, 2024$2.50M-7.1%
Q2 FY2024Jun 30, 2024$2.77M-15.7%
Q1 FY2024Mar 31, 2024$3.06M-10.5%
Q4 FY2023Dec 31, 2023$2.24M-26.4%
Q3 FY2023Sep 30, 2023$2.70M+17.6%
Q2 FY2023Jun 30, 2023$3.28M+39.3%
Q1 FY2023Mar 31, 2023$3.42M+51.3%
Q4 FY2022Dec 31, 2022$3.05M+69.5%
Q3 FY2022Sep 30, 2022$2.29M+35.0%
Q2 FY2022Jun 30, 2022$2.36M+4.4%
Q1 FY2022Mar 31, 2022$2.26M+29.0%
Q4 FY2021Dec 31, 2021$1.80M+252.4%
Q3 FY2021Sep 30, 2021$1.70M+13.3%
Q2 FY2021Jun 30, 2021$2.26M+5.8%
Q1 FY2021Mar 31, 2021$1.75M–
Q4 FY2020Dec 31, 2020$510.00K–
Q3 FY2020Sep 30, 2020$1.50M–
Q2 FY2020Jun 30, 2020$2.13M–

More CVRx figures

See a number that looks wrong?